- Home
- IVP vs RDHL Comparison
IVP vs RDHL Comparison
Compare IVP & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- RDHL
- Stock Information
- Founded
- IVP 2020
- RDHL 2009
- Country
- IVP United States
- RDHL Israel
- Employees
- IVP N/A
- RDHL N/A
- Industry
- IVP Diversified Commercial Services
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- RDHL Health Care
- Exchange
- IVP Nasdaq
- RDHL Nasdaq
- Market Cap
- IVP 3.3M
- RDHL 3.8M
- IPO Year
- IVP 2023
- RDHL N/A
- Fundamental
- Price
- IVP $1.66
- RDHL $1.85
- Analyst Decision
- IVP
- RDHL
- Analyst Count
- IVP 0
- RDHL 0
- Target Price
- IVP N/A
- RDHL N/A
- AVG Volume (30 Days)
- IVP 76.0K
- RDHL 18.5K
- Earning Date
- IVP 08-13-2025
- RDHL 04-10-2025
- Dividend Yield
- IVP N/A
- RDHL N/A
- EPS Growth
- IVP N/A
- RDHL N/A
- EPS
- IVP N/A
- RDHL N/A
- Revenue
- IVP $15,399,751.00
- RDHL $8,042,999.00
- Revenue This Year
- IVP N/A
- RDHL $381.91
- Revenue Next Year
- IVP N/A
- RDHL N/A
- P/E Ratio
- IVP N/A
- RDHL N/A
- Revenue Growth
- IVP N/A
- RDHL 23.17
- 52 Week Low
- IVP $1.26
- RDHL $1.71
- 52 Week High
- IVP $401.50
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- IVP 46.82
- RDHL 43.03
- Support Level
- IVP $1.51
- RDHL $1.72
- Resistance Level
- IVP $1.76
- RDHL $2.08
- Average True Range (ATR)
- IVP 0.13
- RDHL 0.09
- MACD
- IVP -0.02
- RDHL 0.01
- Stochastic Oscillator
- IVP 18.43
- RDHL 27.78
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.